Unlimited Bio

Unlimited Bio is an emerging longevity biotechnology company dedicated to developing next-generation gene therapies for age-related decline and human rejuvenation. Unlike conventional approaches that focus on single targets, the company pursues a combination therapy strategy, recognizing that aging is a multifactorial process requiring interventions across several biological pathways. Its long-term vision is to conduct 100 clinical trials in ten years by leveraging the regulatory flexibility available in Próspera, Honduras. The company's current programs include VEGF gene therapy, designed to improve vascularization and tissue regeneration, and Follistatin gene therapy, aimed at combating sarcopenia and age-related muscle loss. Future programs under development include therapies based on Klotho and BDNF, targeting systemic aging and cognitive function. Unlimited Bio collaborates with organizations such as BioViva and Artgen Biotech and is pursuing combination protocols intended to address multiple hallmarks of aging simultaneously. The company emphasizes rapid clinical translation and innovative regulatory pathways while acknowledging that its therapies remain experimental and are not approved by the FDA.